Travere Revenue Per Share from 2010 to 2025

TVTX Stock  USD 21.13  0.48  2.32%   
Travere Therapeutics Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share will likely drop to 2.62 in 2025. Revenue Per Share is the amount of revenue generated by Travere Therapeutics per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
2.95574048
Current Value
2.62
Quarterly Volatility
1.24640044
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 277.3 M, Other Operating Expenses of 581.5 M or Total Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Travere Therapeutics over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Travere Therapeutics' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.95610 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Travere Revenue Per Share Regression Statistics

Arithmetic Mean2.70
Geometric Mean2.38
Coefficient Of Variation46.11
Mean Deviation1.09
Median2.98
Standard Deviation1.25
Sample Variance1.55
Range3.0455
R-Value0.57
Mean Square Error1.12
R-Squared0.32
Significance0.02
Slope0.15
Total Sum of Squares23.30

Travere Revenue Per Share History

2025 2.62
2024 2.96
2023 1.96
2022 3.33
2021 3.8
2020 4.17
2019 4.14

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 2.96  2.62 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.